Charles E. Argoff , MD, CPE
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
After attending this symposium, participants should be better able to:
- Provide a review of migraine impact, diagnosis, and treatment guidelines
- Review recent information on migraine pathophysiology and the role of CGRP in migraine
- Discuss clinical trial study design and background on AJOVY as an anti-CGRP for the preventive treatment of migraine in adults
- Review the efficacy, safety, and dosing/ administration of AJOVY in clinical trials
During this presentation, faculty will provide an overview of AJOVY® (fremanezumab-vfrm) injection as a preventive treatment of migraine in adults. The presentation will begin with a discussion of the migraine disease state, including migraine pathophysiology. This will be followed by a review of the efficacy and safety of AJOVY. Additionally, participants will have the opportunity to ask questions of the faculty.
IMPORTANT SAFETY_INFORMATION (continued)
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.
Adverse Reactions: The most common adverse reactions (_5% and greater than placebo) were injection site reactions.
Activity sponsored by: Teva Pharmaceuticals